KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Capital Expenditures: 2010-2024

Historic Capital Expenditures for Acadia Pharmaceuticals (ACAD) over the last 14 years, with Dec 2024 value amounting to $523,000.

  • Acadia Pharmaceuticals' Capital Expenditures rose 454.29% to $388,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $912,000, marking a year-over-year decrease of 23.49%. This contributed to the annual value of $523,000 for FY2024, which is 946.00% up from last year.
  • As of FY2024, Acadia Pharmaceuticals' Capital Expenditures stood at $523,000, which was up 946.00% from $50,000 recorded in FY2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Capital Expenditures peaked at $7.6 million during FY2020, and registered a low of $50,000 during FY2023.
  • Moreover, its 2-year median value for Capital Expenditures was $286,500 (2023), whereas its average is $286,500.
  • Its Capital Expenditures has fluctuated over the past 5 years, first tumbled by 85.21% in 2021, then skyrocketed by 946.00% in 2024.
  • Acadia Pharmaceuticals' Capital Expenditures (Yearly) stood at $7.6 million in 2020, then crashed by 85.21% to $1.1 million in 2021, then reached $50,000 in 2023, then skyrocketed by 946.00% to $523,000 in 2024.